Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

NCT05277935 | Recruiting

• 1 other identifier: WEFITTER
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 4

Brief Summary

Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast cancer patients using Palbociclib and endocrine treatment.

Conditions

Breast Neoplasm Female; Quality of Life

Keywords

Quality of life; Metastatic breast cancer; Metastasis; Exercise; Palbociclib

Outcome Measures

Primary Outcomes (4)

• Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast

  Measure the Quality of life of patients with metastatic breast cancer treated with Palbociclib and endocrine therapy using the Functional Assessment of Cancer Therapy - Breast and compare the group using the Wecancer digital health app with the group using Wecancer and the physical activity monitoring smartwatch. The comparison of the two groups in relation to quality of life, measured by the general score of the Functional Assessment of Cancer Therapy - Breast and its sub-items, over time will be made using a linear model withmixed effects, that is, fixed effects and random effects. Time and group fixed effects will be considered, the patient will be considered random effect. The effects of time, group and interaction between them will be tested.

  Baseline

• Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast

  Measure the Quality of life of patients with metastatic breast cancer treated with Palbociclib and endocrine therapy using the Functional Assessment of Cancer Therapy - Breast and compare the group using the Wecancer digital health app with the group using Wecancer and the physical activity monitoring smartwatch. The comparison of the two groups in relation to quality of life, measured by the general score of the Functional Assessment of Cancer Therapy - Breast and its sub-items, over time will be made using a linear model withmixed effects, that is, fixed effects and random effects. Time and group fixed effects will be considered, the patient will be considered random effect. The effects of time, group and interaction between them will be tested.

  Follow up 2 month

• Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast

  Measure the Quality of life of patients with metastatic breast cancer treated with Palbociclib and endocrine therapy using the Functional Assessment of Cancer Therapy - Breast and compare the group using the Wecancer digital health app with the group using Wecancer and the physical activity monitoring smartwatch. The comparison of the two groups in relation to quality of life, measured by the general score of the Functional Assessment of Cancer Therapy - Breast and its sub-items, over time will be made using a linear model withmixed effects, that is, fixed effects and random effects. Time and group fixed effects will be considered, the patient will be considered random effect. The effects of time, group and interaction between them will be tested.

  Follow up 4 month

• Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast

  Measure the Quality of life of patients with metastatic breast cancer treated with Palbociclib and endocrine therapy using the Functional Assessment of Cancer Therapy - Breast and compare the group using the Wecancer digital health app with the group using Wecancer and the physical activity monitoring smartwatch. The comparison of the two groups in relation to quality of life, measured by the general score of the Functional Assessment of Cancer Therapy - Breast and its sub-items, over time will be made using a linear model withmixed effects, that is, fixed effects and random effects. Time and group fixed effects will be considered, the patient will be considered random effect. The effects of time, group and interaction between them will be tested.

  Follow up 6 month

Study Arms (2)

Use of the WeCancer app combined with the smartwatch

ACTIVE COMPARATOR

The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), feedback to the patient in the comments made, guidance on physical and eating exercises, reception and support from the Wecancer multidisciplinary team, consisting of a navigator nurse, psychologist, nutritionist and physiotherapist. During the survey period, participants should report their symptoms on the Wecancer app whenever possible, preferably daily.

Device: Use of the WeCancer app combined with the smartwatch.

Using the WeCancer app

NO INTERVENTION

The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient feedback on the comments made, guidance on physical and dietary exercises, reception and support of the Multidisciplinary cancer team composed of a navigator nurse, a psychologist, nutritionist and physiotherapist. During the research period, participants must report your symptoms in the Wecancer app whenever possible, preferably daily.

Interventions

Use of the WeCancer app combined with the smartwatch. DEVICE

To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy

Use of the WeCancer app combined with the smartwatch

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients ≥ 18 years of age diagnosed with hormone receptor-positive/ human epidermal growth factor receptor 2- negative metastatic breast cancer undergoing treatment with Palbociclib combined with aromatase inhibitors (letrozole, exemestane or anastrozole) or fulvestrant as first-line therapy, or in treatment with Palbociclib and fulvestrant as second-line or posterior-line therapy in the metastatic setting; may be using ovarian suppression if the patient is premenopausal.
• The patient must be on treatment for at least three (3) months with Palbociclib and endocrine therapy.
• Evidence of a signed and dated informed consent document, physically or digitally, indicating that the research participant was informed about all relevant aspects of the study;
• The patient agrees not to participate in another study with drug intervention while on treatment.
• Have performance status according to the Eastern Cooperative Oncology Group
• Have access to a compatible smartphone and 3G or 4G internet connection

You may not qualify if:

• Patients considered to be at poor medical risk due to uncontrolled serious medical disorder, non-malignant systemic disease, or active uncontrolled infection. Examples: uncontrolled ventricular arrhythmia, recent myocardial infarction (within 6 months), stroke, gastrointestinal bleeding, or any psychiatric disorder that precludes informed consent; between others.
• Patients who have a life expectancy of \< 3 months.
• Treatment with any product under investigation during the last 28 days;
• Illiterate patients or those with a low level of education that may prevent the correct use of the Wecancer application and/or the watch with monitoring of physical activity.

Sponsors & Collaborators

• Beneficência Portuguesa de São Paulo: lead

Study Sites (4)

Oncoclínicas

Rio de Janeiro, Brazil

RECRUITING

A Beneficência Portuguesa de São Paulo

São Paulo, Brazil

RECRUITING

A.C.Camargo Cancer Center

São Paulo, Brazil

RECRUITING

Centro Paulista de Oncologia

São Paulo, Brazil

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms; Neoplasm Metastasis; Motor Activity

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Behavior

Study Officials

• Graziela Dal Molin, MD

  Beneficência Portuguesa de São Paulo

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Bianca Verboski

CONTACT

11-35052639; naipe@bp.org.br

Bianca Verboski

CONTACT

11-35052639; bianca.verboski@bp.org.br

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: January 12, 2022
• First Posted: March 14, 2022
• Study Start: April 22, 2022
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: August 26, 2024

Record last verified: 2024-08

Locations

BR (4)